JP2023547274A5 - - Google Patents
Info
- Publication number
- JP2023547274A5 JP2023547274A5 JP2023549131A JP2023549131A JP2023547274A5 JP 2023547274 A5 JP2023547274 A5 JP 2023547274A5 JP 2023549131 A JP2023549131 A JP 2023549131A JP 2023549131 A JP2023549131 A JP 2023549131A JP 2023547274 A5 JP2023547274 A5 JP 2023547274A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mir
- salt
- nucleosides
- guide chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2016863.9A GB202016863D0 (en) | 2020-10-23 | 2020-10-23 | Microrna-29 compounds, compositions and uses in therapy |
| GB2016863.9 | 2020-10-23 | ||
| PCT/EP2021/079580 WO2022084561A2 (en) | 2020-10-23 | 2021-10-25 | Microrna-29 compounds, compositions and uses in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023547274A JP2023547274A (ja) | 2023-11-09 |
| JP2023547274A5 true JP2023547274A5 (enExample) | 2024-11-01 |
Family
ID=73726994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549131A Pending JP2023547274A (ja) | 2020-10-23 | 2021-10-25 | マイクロｒｎａ－２９の化合物、組成物、および治療法における使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240390410A1 (enExample) |
| EP (1) | EP4232580A2 (enExample) |
| JP (1) | JP2023547274A (enExample) |
| KR (1) | KR20230088810A (enExample) |
| CN (1) | CN116744942A (enExample) |
| AU (1) | AU2021365394A1 (enExample) |
| CA (1) | CA3195977A1 (enExample) |
| GB (1) | GB202016863D0 (enExample) |
| WO (1) | WO2022084561A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023445724A1 (en) * | 2023-04-28 | 2025-11-06 | Causeway Therapeutics Limited | Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400598D0 (en) * | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
| CA2949109A1 (en) * | 2014-05-29 | 2015-12-03 | Quark Pharmaceuticals, Inc. | Methods and compositions for preventing ischemia reperfusion injury in organs |
| US9376681B2 (en) * | 2014-09-08 | 2016-06-28 | MiRagen Therapeutics, Inc. | miR-29 mimics and uses thereof |
| GB201503967D0 (en) * | 2015-03-09 | 2015-04-22 | Univ Glasgow | Biocompatible implants for use in tendon therapy |
| US20200318113A1 (en) * | 2019-03-05 | 2020-10-08 | MiRagen Therapeutics, Inc. | Polynucleotide conjugates and uses thereof |
-
2020
- 2020-10-23 GB GBGB2016863.9A patent/GB202016863D0/en not_active Ceased
-
2021
- 2021-10-25 EP EP21801857.0A patent/EP4232580A2/en active Pending
- 2021-10-25 CA CA3195977A patent/CA3195977A1/en active Pending
- 2021-10-25 JP JP2023549131A patent/JP2023547274A/ja active Pending
- 2021-10-25 KR KR1020237016847A patent/KR20230088810A/ko active Pending
- 2021-10-25 CN CN202180087062.9A patent/CN116744942A/zh active Pending
- 2021-10-25 US US18/033,322 patent/US20240390410A1/en active Pending
- 2021-10-25 AU AU2021365394A patent/AU2021365394A1/en active Pending
- 2021-10-25 WO PCT/EP2021/079580 patent/WO2022084561A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agrawal et al. | Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. | |
| DE102006007433A1 (de) | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure | |
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| JPH10507635A (ja) | 遺伝子発現をダウンレギュレートするための２’−置換オリゴヌクレオチドの使用 | |
| KR101975915B1 (ko) | 올리고뉴클레오타이드 킬레이트 복합체 방법 | |
| TWI740866B (zh) | 肽寡核苷酸結合物 | |
| JP2005512976A5 (enExample) | ||
| JP2022536495A5 (enExample) | ||
| JP2019525918A5 (enExample) | ||
| JP2022533358A5 (enExample) | ||
| JP2021532784A (ja) | アンチセンス送達のための三量体ペプチド | |
| EP2207555B1 (en) | Oligonucleotides for the treatment or alleviation of edema | |
| JPH11513992A (ja) | シチジンデアミナーゼまたはデオキシシチジンデアミナーゼの過剰発現を伴う疾患を治療するための薬剤および方法 | |
| JP2024544532A5 (enExample) | ||
| JP2023547274A5 (enExample) | ||
| EP1935428A1 (en) | Oligonucleotide-polymer conjugates | |
| US20030148981A1 (en) | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response | |
| TW202237189A (zh) | 具有增強之肝靶向的ｓ抗原運輸抑制寡核苷酸聚合物之接合物 | |
| US20260103703A1 (en) | siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDS | |
| JP2025504474A5 (enExample) | ||
| CN114127292A (zh) | 减轻反义核酸的毒性的方法 | |
| AU755786B2 (en) | Compositions and methods for the delivery of oligonucleotides via the alimentary canal | |
| JPH0834735A (ja) | 新規抗ｈｉｖ剤 | |
| RU2025125558A (ru) | Способы лечения нарушений нервной системы | |
| JPH0859481A (ja) | 新規抗ｈｉｖ剤 |